ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple therapeutic areas. This comes following feedback from the European Medicines Agency (EMA) related to ProQR’s sepofarsen for Leber Congenital Amaurosis type 10 (LCA10).
… ProQR agreement with Laboratoires Théa for sepofarsen and ultevursen inherited retinal disease programs . Strategic … readout of the modified Phase 2/3 Sirius trial of ultevursen. For a full update, please read our community …
